… expands Asahi Kasei’s specialty pharmaceutical platform further into severe infectious … build a focused, sustainable specialty pharmaceutical platform serving immunocompromised and medically … the drug Marketed (licensed to Merck & Co., Inc. [known as …

… and chief medical officer, Merck Research Laboratories. “Islatravir … for everyone. About Merck At Merck, known as MSD … ; the impact of pharmaceutical industry regulation and health … MANAGED CARE HEALTH PHARMACEUTICAL GENERAL HEALTH SOURCE: Merck & Co., …

… ard-2023-223850. About Merck Animal Health Merck Animal Health, a division … rate fluctuations; the impact of pharmaceutical industry regulation and health care … VETERINARY BIOTECHNOLOGY PHARMACEUTICAL PETS GENERAL HEALTH HEALTH FDA CONSUMER SOURCE: Merck …

Findings from the phase 3 KEYNOTE-B15/EV-304 trial (NCT04700124) revealed significant improvements in event-free survival (EFS), overall survival (OS), and pathological complete responses (pCR) with perioperative enfortumab vedotin-ejfv (EV; Padcev) …

Post-treatment ctDNA negativity or clearance correlated with improved metastasis-free survival among patients with muscle-invasive bladder cancer (MIBC), as those with undetectable ctDNA following treatment experieced a lower risk of systemic recurrence, …

Merck & Co is splitting its main pharmaceutical unit in two … medications in the world. Merck shares were up about … Mizuho. Holz said other pharmaceutical companies, including Pfizer Inc … recent note. In September, Merck snagged US regulatory approval of …